MedTrace Logo

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

NCT06416995 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2024-05-16

No results posted yet for this study

Summary

Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.

Conditions

Interventions

DIAGNOSTIC_TEST

first trimester serum diagnostic test

First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes

Sponsors & Collaborators

  • Umraniye Education and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-03
Primary Completion
2024-11-30
Completion
2024-12-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06416995 on ClinicalTrials.gov